SUZHOU, China, and ROCKVILLE, Md., Nov. 3, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results from multiple clinical studies of the company's novel drug candidate, olverembatinib, have been selected for presentations, including two Oral Reports, at the 65th American Society of Hematology (ASH) Annual Meeting. Being selected for Oral Reports at the ASH Annual Meeting for the sixth consecutive year underscores the significant interest in the drug by the global hematology community. This year, results from multiple clinical studies on two of Ascentage Pharma's lead drug candidates (olverembatinib and lisaftoclax) have been selected for presentations at the ASH Annual Meeting.
As a potential best-in-class drug, olverembatinib has broad therapeutic potential for the treatment of multiple solid tumors and hematologic malignancies. Currently, olverembatinib is being jointly commercialized by Ascentage Pharma and Innovent Biologics. Through an Oral Report at this year's ASH Annual Meeting, Ascentage Pharma will present the latest results from a randomized, controlled registrational Phase II study in patients with first- and second-generation tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia in the chronic-phase (CML-CP), led by Prof. Xiaojun Huang and Prof. Qian Jiang, from the Institute of Hematology of the Peking University People's Hospital. These data show that, in patients with CML-CP who were resistant/intolerant to TKIs, olverembatinib demonstrated statistically significant and clinically meaningful improvement in event-free survival (EFS), compared with the best available therapy (BAT), meeting the primary endpoint of the study.
The other Oral Report featuring early results from a Phase II study of olverembatinib combined with venetoclax and reduced-intensity chemotherapy in treatment-naïve patients with Ph+ ALL, led by Prof. Xiaoyuan Gong of the Institute of Hematology and Blood Diseases Hospital, the Chinese Academy of Medical Sciences
Also at this year's ASH Annual Meeting, Ascentage Pharma will release updated results from a US study of olverembatinib in a Poster Presentation. These data demonstrate the favorable potential clinical benefit of olverembatinib monotherapy and combination regimens in patients with heavily pretreated CML or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and show the drug's therapeutic effect in patients who had failed prior treatment with ponatinib or asciminib, further demonstrating the drug's potential as a new treatment option to patients with CML or Ph+ ALL worldwide.
In addition, multiple studies of olverembatinib were also selected for Poster Presentations, including one featuring a case series study of liposome mitoxantrone combined with venetoclax, homoharringtonine, and olverembatinib (the MVHO regimen) in pediatric patients with refractory or recurrent acute myeloid leukemia (AML), carried out by a team of investigators including Wenting Hu and Prof. Shuhong Shen of the Department of Hematology & Oncology, Shanghai Children's Medical Center of Shanghai Jiao Tong University School of Medicine (see the table below for details).
The ASH Annual Meeting is one of the largest gatherings of the international hematology community, bringing together the latest and most cutting-edge scientific research in the pathogenesis and clinical treatment of hematologic diseases. The 65th ASH Annual Meeting will take place on December 9-12, 2023, local time, both online and in-person in San Diego, CA (United States).
"This is the sixth consecutive year for the updated clinical data of olverembatinib to be accepted for presentation at the ASH Annual Meeting, a new record for the drug," said Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma. "This year, results from multiple studies of olverembatinib have been selected for presentations, including two Oral Reports, at the meeting. This indicates the global hematology community's strong recognition of olverembatinib, a global best-in-class drug. The large body of clinical data we are bringing to this year's ASH Annual Meeting underscores our broad progress in new drug discovery and clinical development. Moving forward, we will continue to expeditiously advance our clinical development programs globally for the benefit of patients in China and around the world."
Studies of Ascentage Pharma's Drug Candidates to be presented at ASH 2023
Drug Candidate |
Title |
PI/Presenter |
Institution |
Abstract# |
Format |
Olverembatinib (HQP1351) |
Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study |
Qian Jiang
Xiaojun Huang |
The Peking University People's Hospital |
#869 |
Oral Report |
Olverembatinib Combined with Venetoclax and Reduced-Intensity Chemotherapy for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Early results from a phase II study |
Xiaoyuan Gong |
Institute of Hematology and Blood Diseases Hospital, the Chinese Academy of Medical Sciences |
#827 |
Oral Report |
|
Update of Olverembatinib (HQP1351) Overcoming Ponatinib and/or Asciminib Resistance in Patients (Pts) with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) |
Elias Jabbour
Hagop Kantarjian |
MD Anderson Cancer Center |
#1798 |
Poster Presentation |
|
Combination of Liposome Mitoxantrone, Venetoclax, Homoharringtonine, and Olverembatinib (HQP1351) (MVHO) in Pediatric Patients with Refractory or Recurrent Acute Myeloid Leukemia (AML): Case Series |
Wenting Hu
Shuhong Shen |
Department of Hematology & Oncology, Shanghai Children's Medical Center of Shanghai Jiao Tong University School of Medicine |
#2840 |
Poster Presentation |
|
Combination of Olverembatinib and VP Regimen As First-Line Therapy for Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia |
Gaixiang Xu
Jie Jin |
The First Affiliated Hospital, Zhejiang University School of Medicine |
#4205 |
Poster Presentation |
|
Olverembatinib(HQP1351)-Based Therapy in Adults with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Advanced Chronic Myeloid Leukemia: Results of the Real-Life Study |
Na Xu |
Nanfang Hospital of Southern Medical University |
#4538 |
Poster Presentation |
|
Frontline Combination of 3 Generation TKI Olverembatinib and Blinatumomab for Ph+/Phlike ALL Patients |
Hongsheng Zhou |
Nanfang Hospital of Southern Medical University |
#1504 |
Poster Presentation |
|
Lisaftoclax APG-2575 |
Updated Efficacy and Safety Results of Lisaftoclax (APG-2575) in Patients (pts) with Heavily Pretreated Chronic Lymphocytic Leukemia (CLL): Pool Analysis of Two Clinical Trials |
Keshu Zhou
Jianyong Li
Jianxiang Wang |
Henan Cancer Hospital,
Jiangsu Province Hospital
Institute of Hematology and Blood Diseases Hospital, the Chinese Academy of Medical Sciences |
#1900 |
Poster Presentation |
Safety and Efficacy of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Relapsed or Refractory (R/R) or Treatment-Naïve (TN) Patients (Pts) with Acute Myeloid leukemia (AML), Myelodysplastic Syndrome (MDS), or Other Myeloid Neoplasms |
Huafeng Wang
Jie Jin |
The First Affiliated Hospital, Zhejiang University School of Medicine |
#2925 |
Poster Presentation |
|
First Report on the Effects of Lisaftoclax (APG-2575) in Combination with Novel Therapeutic Regimens in Patients with Relapsed or Refractory Multiple Myeloma (R/R MM) or Immunoglobulin Light-Chain (Amyloid Light-Chain [AL]) Amyloidosis |
Sikander Ailawadhi
Asher A. Chanan-Khan |
Mayo Clinic |
#2016 |
Poster Presentation |
Abtracts on olverembatinib presented at the 2023 ASH Annual Meeting are as follows (for details on the abstracts featuring lisaftoclax, please refer to a separate press release published at the same time):
Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study
Format: Oral Report
Abstract: #869
Session: 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Novel Therapeutic Approaches
Time: December 11, 2023, Monday, 3:45 PM (Pacific Time) / December 12, 2023, Tuesday, 7:45 AM (Beijing Time)
Highlights:
Update of Olverembatinib (HQP1351) Overcoming Ponatinib and/or Asciminib Resistance in Patients (Pts) with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Format: Poster Presentation
Abstract: #1798
Session: 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster I
Time: December 9, 2023, Saturday, 5:30 PM - 7:30 PM (Pacific Time) / December 10, 2023, Sunday, 9:30 AM – 11:30 AM (Beijing Time)
Highlights
Olverembatinib Combined with Venetoclax and Reduced-Intensity Chemotherapy for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Early results from a phase II study
Format: Oral Report
Abstract: #827
Session: 614. Acute Lymphoblastic Leukemia: Therapies, Excluding Transplantation and Cellular Immunotherapies: Optimal Frontline Treatment for ALL
Time: December 11, 2023, Monday; 3:45 PM (Pacific Time) / December 12, 2023, Tuesday; 7:45 AM (Beijing Time)
Highlights:
Combination of Liposome Mitoxantrone, Venetoclax, Homoharringtonine, and Olverembatinib (HQP1351) (MVHO) in Pediatric Patients with Refractory or Recurrent Acute Myeloid Leukemia (AML): Case Series
Format: Poster Presentation
Abstract: #2840
Session: 613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster II
Time: December 10, 2023, Sunday, 6:00 PM - 8:00 PM (Pacific Time) / December 11, 2023, Monday, 10:00 AM – 12:00 PM (Beijing Time)
Highlights:
* Olverembatinib is an investigational drug that has not been approved for any indication outside the Chinese mainland
About Ascentage Pharma
Ascentage Pharma (6855.HK) is a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases. On October 28, 2019, Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code 6855.HK.
Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The company has built a pipeline of 9 clinical drug candidates, including novel, highly potent Bcl-2, and dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs). Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators. The company is conducting more than 40 Phase I/II clinical trials in the US, Australia, Europe, and China. Ascentage Pharma has been designated for multiple Major National R&D Projects, including five Major New Drug Projects, one New Drug Incubator status, four Innovative Drug Programs, and one Major Project for the Prevention and Treatment of Infectious Diseases.
Olverembatinib, the company's core drug candidate developed for the treatment of drug-resistant chronic myeloid leukemia (CML) and the company's first approved product, has been granted Priority Review Designations and Breakthrough Therapy Designations by the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA). To date, the drug had been included into the China 2022 National Reimbursement Drug List (NRDL). Furthermore, olverembatinib has been granted an Orphan Drug Designation (ODD) and a Fast Track Designation (FTD) by the US FDA, and an Orphan Designation by the EMA of the EU. To date, Ascentage Pharma has obtained a total of 16 ODDs, 2 FTDs, and 2 Rare Pediatric Disease (RPD) Designations from the US FDA and 1 Orphan Designation from the EMA of the EU for 4 of the company's investigational drug candidates.
Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships with numerous renowned biotechnology and pharmaceutical companies and research institutes such as UNITY Biotechnology, MD Anderson Cancer Center, Mayo Clinic, Dana-Farber Cancer Institute, MSD, and AstraZeneca. The company has built a talented team with global experience in the discovery and development of innovative drugs and is setting up its world-class commercial manufacturing and Sales & Marketing teams. One pivotal aim of Ascentage Pharma is to continuously strengthen its R&D capabilities and accelerate its clinical development programs, in order to fulfil its mission of addressing unmet clinical needs in China and around the world for the benefit of more patients.
Forward-Looking Statements
The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, Ascentage Pharma undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.